Iovance Biotherapeutics
IOVA
295 hedge funds and large institutions have $1.86B invested in Iovance Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 115 increasing their positions, 80 reducing their positions, and 41 closing their positions.
63% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 41
44% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 80
36% more call options, than puts
Call options by funds: $25.3M | Put options by funds: $18.5M
8% more funds holding
Funds holding: 273 → 295 (+22)
5.32% more ownership
Funds ownership: 77.78% → 83.1% (+5.3%)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
42% less capital invested
Capital invested by funds: $3.22B → $1.86B (-$1.35B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$71.4M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$43.3M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$35.8M |
| 4 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$29.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$23.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
-$25M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$22M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.1M |
| 4 |
D.E. Shaw & Co
New York
|
-$18.2M |
| 5 |
Millennium Management
New York
|
-$15.5M |
IOVA Hedge Fund Activity: Q2 2024 in Review
295 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2024, worth a combined $1.86B — down 42% from $3.22B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new IOVA positions and 41 closed out — a net gain of 26 holders — while 115 added to existing stakes and 80 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $71.4M. The largest seller was Pictet Asset Management, cutting an estimated $25M.
- 295 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2024, up from 273 in Q1 2024.
- Funds reported $1.86B of Iovance Biotherapeutics stock for Q2 2024, down 42% quarter-over-quarter.
- 67 funds opened new Iovance Biotherapeutics positions in Q2 2024 and 41 closed out, a net change of +26 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2024 was Perceptive Advisors, an estimated $71.4M added.
- The largest Iovance Biotherapeutics seller in Q2 2024 was Pictet Asset Management, an estimated $25M sold.
Based on aggregated 13F filings for Q2 2024.